- Home
- KIO vs VSTM Comparison
KIO vs VSTM Comparison
Compare KIO & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KIO | VSTM |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.1M | 470.7M |
| IPO Year | 2011 | 2011 |
Fundamental Metrics
Financial Performance| Metric | KIO | VSTM |
|---|---|---|
| Price | $11.12 | $6.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 246.9K | ★ 2.1M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $282.64 |
| Revenue Next Year | N/A | $72.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $10.65 | $4.01 |
| 52 Week High | $12.83 | $11.25 |
Technical Indicators
Market Signals| Indicator | KIO | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 58.45 |
| Support Level | $10.66 | $6.01 |
| Resistance Level | $11.24 | $6.79 |
| Average True Range (ATR) | 0.17 | 0.39 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 77.97 | 97.40 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.